Use of PI3KC2B inhibitors for the preservation of vascular endothelial cell barrier integrity
US12123000B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 14, 2019 |
| Grant date | Oct 22, 2024 |
| Priority date | — |
| Expiry date | Jul 25, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/91215
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Ischemic conditions are a leading cause of death for both men and women. Ischemia, a condition characterized by reduced blood flow and oxygen to an organ. Re-establishment of blood flow, or reperfusion, and re-oxygenation of the affected area following an ischemic episode is critical to limit irreversible damage. However, reperfusion also associates potentially damaging consequences. For instance, increased vascular permeability is an important contributor to edema and tissue damage following ischemic events. Here the inventors shows that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion (I/R) models and improves neurological outcome. The genetic inhibition stabilizes the blood-brain barrier (BBB) after ischemic stroke and reduces inflammation. Accordingly, the present invention relates to a method for the preservation of vascular endothelial cell barrier integrity in a patient in need thereof comprising administering to the subject a therapeutically effective amount of a PI3KC2β inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.